Literature DB >> 32249037

Evidence based treatment for developmental dysplasia of the hip in children under 6 months of age. Systematic review and exploratory analysis.

Maryam Ashoor1, Nada Abdulla2, Elham Ahmed Elgabaly3, Ehab Aldlyami4, Sattar Alshryda3.   

Abstract

INTRODUCTION: Developmental dysplasia of the hip (DDH) is a common paediatric orthopaedic condition that attracts a substantive amount of controversy. The treatments vary because of the wide spectrum of the condition and the age of children at presentation. Although conservative and surgical treatments exist; it is widely accepted that conservative treatment is the first line of treatment in the first 6 months of life. Several devices have been proposed as the treatment of choice; however, to the best of our knowledge these have not been critically appraised. Therefore, we conducted this review.
METHODS: A modified Cochrane method was followed with a preplanned detailed research protocol that was developed to guide all aspects of the review. Treatment failure of the devices was chosen as the primary outcome. Secondary outcomes included femoral nerve palsy (FNP), avascular necrosis of the femoral head (AVN), residual dysplasia, skin problems, failure of subsequent surgical treatment, compliance and tolerance issues. Results are reported according to the PRISMA guidelines.
RESULTS: A total of 30 studies were included in the review comparing 5 devices (The Pavlik harness, the Von Rosen splint, the Tubingen brace, the Frejka pillow, and the Aberdeen splint). The devices were compared in terms of success rate, AVN rate and residual dysplasia. The von Rosen splint has been shown to be superior to other devices in term of success rates and residual dysplasia (Χ2: P < 0.05).
CONCLUSION: The review findings should be interpreted with caution as there are substantive flaws in the literature and a randomized control trail is warranted to confirm the best device to treat DDH. This is feasible given the magnitude of the problem, the clear diagnostic criteria and the treatment options.
Copyright © 2020 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DDH; Developmental dysplasia of the hip; Orthopaedics

Year:  2020        PMID: 32249037     DOI: 10.1016/j.surge.2020.02.006

Source DB:  PubMed          Journal:  Surgeon        ISSN: 1479-666X            Impact factor:   2.392


  5 in total

Review 1.  Splinting for the non-operative management of developmental dysplasia of the hip (DDH) in children under six months of age.

Authors:  Kerry Dwan; Jamie Kirkham; Robin W Paton; Emma Morley; Ashley William Newton; Daniel C Perry
Journal:  Cochrane Database Syst Rev       Date:  2022-10-10

2.  Children treated for developmental dysplasia of the hip at birth and with normal acetabular index at 1 year: How many had residual dysplasia at 5 years?

Authors:  Øyvind Håberg; Thomas Bremnes; Olav A Foss; Oskar Angenete; Øystein B Lian; Ketil J Holen
Journal:  J Child Orthop       Date:  2022-06-30       Impact factor: 1.917

3.  Tübingen hip flexion splint for the treatment of developmental dysplasia of the hip in children younger than six months age: a meta-analysis.

Authors:  Xinwang Zhi; Xietian Xiao; Yuwei Wan; Ping Wei; Federico Canavese; Hongwen Xu
Journal:  J Child Orthop       Date:  2021-08-20       Impact factor: 1.548

4.  Splint Duration and Not the Mode of Anesthesia Is the Main Factor Influencing Avascular Necrosis After Closed Reduction for Developmental Dysplasia of the Hip in Kosovo.

Authors:  Sabit Sllamniku; Besiana P Beqo; Islam Krasniqi; Azem Tërshana; Ardiana Murtezani; Franz Quehenberger; Emir Q Haxhija
Journal:  Front Pediatr       Date:  2022-04-26       Impact factor: 3.569

5.  Observation of the effects of three methods for reducing perineal swelling in children with developmental hip dislocation.

Authors:  Ling Wang; Ning Wang; Mei-Ying He; Hai-Lun Liu; Xian-Qiang Wang
Journal:  World J Clin Cases       Date:  2020-10-26       Impact factor: 1.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.